Results 261 to 270 of about 205,233 (331)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Constraining Endomorphin-1 by β,α-Hybrid Dipeptide/Heterocycle Scaffolds: Identification of a Novel κ-Opioid Receptor Selective Partial Agonist

, 2018
Rossella De Marco, Andrea Bedini, Santi Spampinato, Lorenzo Comellini, Junwei Zhao, Roberto Artali, Luca Gentilucci   +6 more
openalex   +2 more sources

Cascade‐Responsive MXene@Cu‐MOF Heterostructure Integrates Antioxidant Activity, Infection Control, and Vascularization for Tracheal Repair

Advanced Science, EarlyView.
A cascade‐responsive MXene@Cu‐MOF/GelMA hydrogel is engineered as a “skeleton–backpack” platform for extensive tracheal repair. The MXene framework scavenges postoperative ROS and converts NIR light into mild hyperthermia, while the Cu‐MOF component provides pH/NIR‐responsive Cu2+ dosing for infection control, angiogenesis, and chondrogenesis.
Liang Guo, Yingran Shen, Jiaoyu Yi, Juanjuan Li, Ziming Wang, Erji Gao, Siqiang Zheng, Zhe‐Sheng Chen, Bo Tao   +8 more
wiley   +1 more source

The Nicotinic Acetylcholine Receptor Partial Agonist Varenicline Increases the Ataxic and Sedative‐Hypnotic Effects of Acute Ethanol Administration in C57BL/6J Mice

, 2010
Helen M. Kamens, Jimena Andersen, Marina R. Picciotto   +2 more
openalex   +2 more sources

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ. [PDF]

Biomolecules, 2020
Ahn S, Jang DM, Park SC, An S, Shin J, Han BW, Noh M.   +6 more
europepmc   +1 more source

Discovery of Polypharmacological Melanocortin-3 and -4 Receptor Probes and Identification of a 100-Fold Selective nM MC3R Agonist versus a μM MC4R Partial Agonist

, 2019
Katlyn A. Fleming, Katie T. Freeman, Mike D. Powers, Radleigh G. Santos, Ginamarie Debevec, Marc A. Giulianotti, Richard A. Houghten, Skye R. Doering, Clemencia Pinilla, Carrie Haskell‐Luevano   +9 more
openalex   +1 more source

A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease

Advanced Science, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic intestinal inflammation and impaired barrier function, for which effective long‐term therapies remain elusive. To address this challenge, we developed a novel nano‐vaccine that combines Prussian blue nanozymes (PBNZs) adjuvants with a ferritin carrier loaded with ...
Jingyi Sheng, Yubo Huang, Xinyue Li, Yin Liu, Yuehuang Wu, Yuxin Zhang, Ning Gu   +6 more
wiley   +1 more source

5‘-O-Alkyl Ethers of N,2-Substituted Adenosine Derivatives:  Partial Agonists for the Adenosine A₁ and A₃ Receptors

, 2001
Erica W. van Tilburg, Pieter A. M. van der Klein, Jacobien von Frijtag Drabbe Künzel, Miriam de Groote, Christina Stannek, Anna Lorenzen, Adriaan P. IJzerman   +6 more
openalex   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source